Clinical trials: IgG4 Related Disease
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497387
- Testing
- PRG-1801
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Autoimmune Diseases
Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
This study has been designed as a 18-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in active IgG4-RD patients with internal organ involvement…
- Trial name
- NCT05789017
- Testing
- Prednisone and Mycophenolate Mofetil, Mycophenolate Mofetil, Leflunomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Immunoglobulin G4 Related Disease
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD).
- Trial name
- NCT04520451
- Testing
- rilzabrutinib, Glucocorticoids
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Autoimmune Disease
Leflunomide Treatment for IgG4-RD
This study is an open-label randomized controlled trial aiming to investigate whether the efficacy and side effect of Leflunpomide plus glucocorticoid.
- Trial name
- NCT03715699
- Testing
- Prednisone, Prednisone and Leflunomide
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
IgG4 Related Disease
Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
The goal of this clinical trial is to learn if tripterygium wilfordii added to prednisone can treat active IgG4-related disease (IgG4-RD) in adults 45 to 80 years of age. Women in the study must be postmenopausal.
- Trial name
- NCT07878585
- Testing
- Prednisone, tripterygium wilfordii
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Peking Union Medical College Hospital
Undiagnosed IgG4 Related Diseases
Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.
Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.
- Trial name
- NCT02229448
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Meir Medical Center
IgG4 Related Disease, Covid19
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
Since December 2019, coronavirus disease 2019 (COVID-19), caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than 124 million people worldwide as of 23/3/2021.
- Trial name
- IgG4-COVID (NCT04817553)
- Testing
- exposure to COVID19
- Where
- Hong Kong
- Volunteers
- 124 people
- Sponsor
- Chinese University of Hong Kong
IgG4-Related Diseases
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
This study intends to use the new technology of fibroblast activation protein PET / CT to study whether the tiny residual lesions detected by 68Ga-FAPI PET / CT are related to the recurrence of IgG4-RD in patients with IgG4-RD…
- Trial name
- NCT07104058
- Testing
- 68Ga-FAPI PET / CT
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Luo Yaping
Behcet's Disease, Idiopathic Inflammatory Myopathies
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations.
- Conditions
- Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
- Trial name
- DRIMID (NCT06285539)
- Testing
- Filgotinib
- Where
- 6 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
IgG4 Related Disease
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).
- Trial name
- NCT04540497
- Testing
- Inebilizumab
- Where
- 72 sites in United States, Argentina and 19 more
- Volunteers
- 135 people
- Sponsor
- Amgen
IgG4 Related Disease
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and…
- Trial name
- IgG4-RD (NCT07068165)
- Testing
- 5mg lenalidomide, 10mg lenalidomide, Prednisone monotherapy
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College Hospital
IgG4-related Disease
Glucocorticoids in Patients With IgG4-RD
This is a randomized, open-label, single-center clinical trial to compare the efficacy and safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related Disease.
- Trial name
- NCT01758393
- Testing
- Prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497361
- Testing
- PRG-2311
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
IgG4 Related Disease
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.
- Trial name
- NCT07298590
- Testing
- CD19/BCMA CAR NK
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
IgG4-related Disease
Tofatib Treatment for IgG4-related Disease
Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.
- Trial name
- NCT05625581
- Testing
- tofacitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
IgG4-related Disease
Study of Sirolimus in IgG4-related Disease
gG4-related disease (IgG4-RD) is a newly recognized systemic autoimmune disease that can involve the pan-creatobiliary tract, retroperitoneum/aorta, head and neck region, and salivary glands, et al.
- Trial name
- NCT05746689
- Testing
- Sirolimus
- Volunteers
- 20 people
- Sponsor
- Peking University International Hospital
Immunoglobulin G4-Related Disease
Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs.
- Trial name
- LENITY (NCT07719543)
- Testing
- Lenalidomide
- Where
- 3 sites in China
- Volunteers
- 146 people
- Sponsor
- Chinese PLA General Hospital
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease
- Trial name
- NCT06361745
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.